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SPG7 MUTATIONS ARE A COMMON CAUSE OF
UNDIAGNOSED ATAXIA
Late-onset ataxias are clinically and etiologically
diverse. Patients rarely have defining clinical features,
and many remain classified as idiopathic, despite
extensive clinical, metabolic, and genetic investiga-
tions. Here we show that mutations in a gene known
to cause hereditary spastic paraplegia (SPG7) are a
major cause of unexplained ataxia presenting in
mid-adult life.
Methods. Exome sequencing in 2 undiagnosed
ataxia patients identified compound heterozygous
SPG7 mutations, not previously considered likely
in the absence of pyramidal signs. This prompted
us to prospectively study SPG7 in 70 other pro-
bands with undiagnosed ataxia and pyramidal signs
attending routine follow-up over a 12-month
period. Other sporadic and inherited causes of
ataxia were excluded, including inflammatory,
metabolic, neoplastic, and sporadic degenerative
ataxia; spinocerebellar ataxia 1, 2, 3, 6, 7, 10, 12,
and 17; dentatorubral-pallidoluysian atrophy; and
Friedreich ataxia. Mutations in SPG7 were detected
by Sanger sequencing of all 17 coding exons and
multiplex ligation-dependent probe amplification
analysis (MRC-Holland kit P213-B1, Amsterdam,
the Netherlands). All patients provided written
informed consent.
Results. Exome sequencing identified 2 SPG7
mutations in patient 1 (c.1529C.T/p.Ala510Val
and c.1715C.T/p.Ala572Val) and 2 in patient 3
(c.1529C.T/p.Ala510Val and c.1192C.T/p.
Arg398*). These were confirmed by Sanger sequenc-
ing, and present in their affected siblings (patients 2
and P4, respectively). The variants were heterozygous
in the unaffected parents, and were previously re-
ported as pathogenic.1 No other recessive mutations
in relevant disease genes were identified (tables e-1 to
e-4 on the Neurology® Web site at Neurology.org).
Of the 70 patients subsequently studied, 13 had
likely recessive mutations (4 homozygous and 9
compound heterozygous). Two patients had novel
mutations (c.1225_1229del/p.Glu409Arg_fs49* and
c.2228T.C/p.Ile743Thr). All patients had the
c.1529C.T/p.Ala510Val mutation on at least one
allele. All patients were of British descent. No rear-
rangements were detected. The clinical features are
summarized in table 1.
At initial presentation, all the patients presented
with symptoms of ataxia or gait disturbance (mean
age 36.3 years, SD 12.5). Midline ataxia was present
in all patients at onset, with gait ataxia present in all
patients and ocular signs in 5. Eleven patients
(65%) had no pyramidal signs (normal reflexes, and
no spasticity). Ocular findings were present in 5
(29%) patients.
On follow-up examination, most patients (76%)
developed appendicular ataxia. All developed clear
pyramidal signs: 12 had overt spasticity, and the
remainder developed brisk tendon reflexes or extensor
plantar responses. Ocular findings were present in 11
(65%), with nystagmus being the most common
finding and partial ophthalmoparesis or slow saccades
in 7 (41%). Twelve patients had brain MRI, with 11
(93%) showing cerebellar atrophy. Cervical spine
MRI (n 5 5) was normal in 4, with 1 patient having
a likely incidental thoracic syrinx. Muscle biopsy
identified cytochrome c oxidase–negative fibers in 2
patients, multiple mtDNA deletions in 1 patient, and
coenzyme Q10 deficiency in a single patient.
Discussion. We were surprised to find likely patho-
genic SPG7 mutations in 18.6% of patients with
unexplained ataxia. Although these patients did not
have pure ataxia on follow-up, it was the
predominating feature, and the patients had been
clinically diagnosed and investigated for ataxic
disorders. In our SPG7 patients, even after an
average follow-up of 16.8 years, the pyramidal signs
were subtle in many, endorsing our conclusion that a
gene identified in patients with autosomal recessive
hereditary spastic paraplegia should be considered in
adults with unexplained ataxia. Eight (57%) of the
probands had no relevant family history, so SPG7
should even be considered in sporadic cases.
Combining these findings with another novel
clinical presentation of SPG7,2 we provide the
first minimum prevalence of SPG7-related disease at
0.72/100,000, making this a common cause of
inherited ataxia, comparable with both autosomal
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Table 1 Clinical features and molecular findings in 17 patients with SPG7 mutations
Patient no. Mutation 1 Mutation 2 First symptom Onset age, y FHx
1 c.1529C.T, p.Ala510Val c.1715C.T, p.(Ala572Val) Ataxia 35 Patient 2
2 c.1529C.T, p.Ala510Val c.1715C.T, p.(Ala572Val) Ataxia 35 Patient 1
3 c.1529C.T, p.Ala510Val c.1192C.T, p.Arg398* Ataxia 25 Patient 4
4 c.1529C.T, p.Ala510Val c.1192C.T, p.Arg398* Ataxia 28 Patient 3
5 c.1529C.T, p.Ala510Val c.233T.A, p.(Leu78*) Gait imbalance 33
6 c.1529C.T, p.Ala510Val c.1715C.T, p.(Ala572Val) Clumsy hands 32 Sibling
7 c.1529C.T, p.Ala510Val c.1715C.T, p.(Ala572Val) Gait imbalance 45 Sibling
8 c.1529C.T, p.Ala510Val c.1529C.T, p.Ala510Val Clumsy Teens
9 c.1529C.T, p.Ala510Val c.2228T.C, p.(Ile743Thr) Gait imbalance, dysarthria 29
10 c.1529C.T, p.Ala510Val c.1529C.T, p.Ala510Val Clumsy 10
11 c.1529C.T, p.Ala510Val c.1053dup, p.(Gly352Argfs*44) Gait imbalance 49
12 c.1529C.T, p.Ala510Val c.1225_1229del, p.(Glu409Argfs*49) Gait imbalance 54 Sibling
13 c.1529C.T, p.Ala510Val c.1529C.T, p.Ala510Val Gait imbalance 46
14 c.1529C.T, p.Ala510Val c.1529C.T, p.Ala510Val Gait imbalance, dysarthria 46
15 c.1529C.T, p.Ala510Val c.1715C.T, p.(Ala572Val) Dysarthria 18
16 c.1529C.T, p.Ala510Val c.1053dup, p.(Gly352Argfs*44) Gait imbalance Childhood Sibling
17 c.1529C.T, p.Ala510Val c.1053dup, p.(Gly352Argfs*44) Balance 40 Sibling
Patient no.
Signs at presentation
Ataxia Weakness Hyperreflexia EPR Spasticity Cerebellar dysarthria Ocular Bladder
1 L/G 31 1 Nystagmus
2 L/G
3 G 31 Mild 1
4 G 31 Mild 1
5 G 31 1 LE
6 L/G
7 G 31 Sac
8 G Nystagmus
9 G
10 L/G Fr
11 G
12 L/G 41 31
13 G
14 G 1 Sac
15 G 1
16 G
17 G 1 Dip
Patient no.
Signs at last follow-up
Interval, y Ataxia Weakness Hyperreflexia EPR Spasticity Cerebellar dysarthria Ocular Bladder
1 9 L/G 31 1 LE 1 Nystagmus U/I
2 13 L/G 41 LE 1 Nystagmus
3 23 G 31 LE 1
4 18 G 31 LE 1
5 12 L/G 41 1 UE/LE 1 PEO, nystagmus
6 15 L/G 41 1 LE 1 PEO U
Continued
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dominant spinocerebellar ataxia (1.59/100,000)3 and
Friedrich ataxia (1.8/100,000).4 This is probably an
underestimate given the late presentation of some
cases. All of our patients had p.Ala510Val,
reaffirming the pathogenicity of this allele, which
has been considered a low frequency polymorphism
(0.3463% in EVS, dbSNP rs61755320). This study
illustrates the advantage of exome sequencing in
neurogenetic disorders, where genes initially shown
to cause one classical phenotype (such as hereditary
spastic paraplegia) can also cause other phenotypes in
a subgroup of patients (such as ataxia).
SPG7 encodes paraplegin, which is a component of
the mitochondrial AAA protease, and the binding part-
ner of AFG3L2.5 Both paraplegin and AFG3L2 are
highly expressed in Purkinje neurons,6 and mutations
in AFG3L2 cause spinocerebellar ataxia type 28.7 This
explains why the phenotypic spectrum of SPG7 in-
cludes a predominantly ataxic presentation. It will be
interesting to see whether specific mutations predispose
to an ataxic or spastic presentation when cohorts
increase in size. However, given the diverse nature of
the clinical presentations, a more inclusive disease name
such as parapleginopathy may avoid the misleading
expectation that spasticity always predominates in this
condition. Future study should address the relative like-
lihoods of these various presentations along the pheno-
typic spectrum of paraplegin-related diseases.
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Table 1 Continued
Patient no.
Signs at last follow-up
Interval, y Ataxia Weakness Hyperreflexia EPR Spasticity Cerebellar dysarthria Ocular Bladder
7 5 L/G 31 LE Sac
8 20 L/G 31 1 Nystagmus
9 5 G 41 1 LE 1
10 27 L/G 31 1 LE 1 PEO, Sac, OA
11 3 L/G 41 UE/LE 1
12 50 L/G 41 31 1 LE PEO
13 8 G 31 1 LE 1 Sac DI
14 3 G..L 31 6 1 Nystagmus
15 25 L/G 31 UE/LE 1
16 35 L/G 31 1 LE Fr
17 23 L/G 21 1 1 PEO, nystagmus
Abbreviations: DI 5 detrusor instability; EPR 5 extensor plantar response; FHx 5 family history; Fr 5 frequency; G 5 gait; I 5 incontinence; L 5 limb;
LE 5 lower extremity; OA 5 optic atrophy; PEO 5 ophthalmoparesis; Sac 5 slow saccades; U 5 urgency; UE 5 upper extremity.
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ANTI-MOG ANTIBODIES WITH LONGITUDINALLY
EXTENSIVE TRANSVERSE MYELITIS PRECEDED
BY CLIPPERS
Chronic lymphocytic inflammation with pontine
perivascular enhancement responsive to steroids
(CLIPPERS) is an inflammatory brainstem syndrome
of uncertain etiology, with distinct radiologic features.1
Autoimmunity has been postulated, although specific
CNS antibodies have not been reported. Our patient
initially presented with classical clinicoradiologic fea-
tures of CLIPPERS. Five months later, she developed a
longitudinally extensive spinal cord inflammatory
lesion affecting mainly the conus, and had antibodies
to myelin-oligodendrocyte glycoprotein (MOG).
Although neuromyelitis optica spectrum disorders
(NMOSD) with brainstem involvement may feature
in the broad differential diagnosis of CLIPPERS, this is
the first report describing an overlap with the anti-
MOG phenotype of NMOSD, and highlights that
CLIPPERS may not be a distinct nosologic entity.
Case report. A 36-year-old woman presented with a
2-week history of dizziness, left facial paresthesia,
allodynia, and altered intraoral sensation. Shortly
before admission, she developed slurred speech,
gait ataxia, and double vision. There were no
constitutional symptoms suggesting systemic illness.
Examination revealed diplopia, horizontal nystag-
mus on left gaze, dysarthria, and left-sided facial
weakness. Visual acuities and fundal appearances
were normal, as were tone, power, sensation, and
sphincter function. Limb reflexes were brisk, without
clonus. Her gait was ataxic.
Brain MRI showed patchy pontocerebellar signal
change (figure, A–D), consistent with CLIPPERS.1
CT of the chest/abdomen/pelvis was normal. CSF
showed 2 lymphocytes/mL and elevated protein
(686 mg/L). Microscopy, culture, and viral PCR were
negative. Flow cytometry identified reactive T cells
(CD4:CD8 ratio 3:1). CSF oligoclonal bands were neg-
ative. Angiotensin converting enzyme levels were nor-
mal, and antinuclear antibody screening was negative.
As symptoms were progressing, we commenced
treatment with high-dose steroids (3 days IV methyl-
prednisolone; thereafter 1 mg/kg/day prednisolone).
Subsequently, the clinical findings and imaging
appearances improved markedly (figure, E).
With full symptom resolution, steroids were slowly
weaned and discontinued 5 months after initial admis-
sion. Two weeks later, the patient developed progress-
ive painful tightness in both legs, altered perineal
sensation, difficulty climbing stairs, and transient
urinary retention requiring catheterization. She had a
spastic paraparesis, pyramidal weakness, brisk 4-limb
reflexes, crossed adductor jerks, and bilateral patellar
and ankle clonus. Left leg pinprick and temperature
sensation were reduced. Upper limb, cranial nerve,
and cerebellar examination results were normal.
MRI showed residual pontine changes and a new
long cord lesion involving the conus (figure, F).
CSF studies revealed 18 lymphocytes, elevated
protein (554 mg/L), and again a reactive picture with-
out clonality on flow cytometry. Oligoclonal bands
remained negative.
Aquaporin-4 (AQP4) antibodies were negative,
but serum anti-MOG immunoglobulin G1 antibod-
ies were positive using a cell-based assay using full-
length human MOG.
Our patient received further pulsed and mainte-
nance steroids. One month later, her myelopathic
symptoms had fully resolved.
Discussion. The initial presentation of a steroid-
responsive brainstem encephalitis with curvilinear
and nodular pontocerebellar enhancement and
T-cell-predominant CSF leukocytosis suggested
CLIPPERS syndrome.1
Alternative diagnoses included autoimmune or
parainfectious disorders, neoplasia (particularly pri-
mary CNS lymphoma), vasculitis, and infection.
Central pontine myelinolysis can occasionally
enhance, but there were no precipitating factors,
and the lesion appearances are atypical. Behçet or
sarcoidosis can cause multifocal lesions, but there
were no systemic features raising suspicion of these
(e.g., orogenital ulceration, uveitis, skin, joint, or res-
piratory involvement). Paraneoplastic antibodies were
not screened; however, the subsequent clinical course
was not suggestive of a paraneoplastic etiology. Given
unequivocal and rapid improvement with steroids,
brainstem biopsy to exclude malignancy was believed
to be of unacceptably high risk.
Although often monophasic, CLIPPERS can
relapse after discontinuation of immunotherapy and
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